The Relative Role of Lipopolysaccharide and Capsule in the Virulence of E. Coli

  • A. Cross
  • J. Sadoff
  • P. Gemski
  • Kwang Sik Kim
Part of the NATO ASI Series book series (volume 24)


E. coli is the leading cause of Gram-negative bacteremia and of neonatal meningitis. In order to cause these extra-intestinally invasive infections, E. coli must traverse the gut, its normal habitat, (or from a common site of infection, the genitourinary tract), into the blood and multiply. These events require a diverse array of bacterial factors, including adhesins, iron-seeking organelles and perhaps enzymes. Extra-intestinal invasion by E. coli also requires that the organism be able to evade normal host defenses, which include serum bacteriolytic and phagocytic mechanisms. For these latter events two moieties of the bacterial outer envelope, the capsule and lipopolysaccharide (LPS) have long been considered to be important virulence factors.*


Capsular Polysaccharide Lethal Infection Specific Bacteriophage Walter Reed Army Institute Rocket Immunoelectrophoresis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Subbaiah, T.V. and Stocker, B.A.D, Rough mutants of Salmonella tvphimurium. 1. Genetics. Nature London 201: 1298–1299 (1964).CrossRefGoogle Scholar
  2. 2.
    Cross, A.S., Gemshi, P., Sadoff, J.C., Orskov, F., and Orskov, I., The importance of the K1 capsule in invasive infections caused by Escherichia coli. J Infect Dis 149: 184–193 (1984).PubMedCrossRefGoogle Scholar
  3. 3.
    Gross, R.J., Cheasty, T., and Rowe, B., Isolation of bacteriophages specific for the K1 polysaccharide antigen of Escherichia coli. J Clin Microbiol 6: 548–550 (1977).PubMedGoogle Scholar
  4. 4.
    Gemski, P., Cross, A.S., and Sadoff, J.C., K1 antigen-associated resistance to the bactericidal activity of serum. FEMS Microbiol Letts 9: 193–197 (1980).CrossRefGoogle Scholar
  5. 5.
    Cross, A.S., Kim, K.S., Wright, D.W., Sadoff, J.C., Gemski, P., Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains E. coli. J Infect Dis 154: 497–503 (1986).Google Scholar
  6. 6.
    Kim, K.S., Kang, J.H., Cross, A.S., The role of capsular antigens in serum resistance and in vivo virulence of Escherichia coli. FEMS Microbiol Letts 35: 275–278 (1986).CrossRefGoogle Scholar
  7. 7.
    Taylor, P.W.and Robinson, M.D., Determinants that increase the serum resistance of Escherichia coli. Infect Immun 29: 278–280 (1980).Google Scholar
  8. 8.
    Opal, S., Cross, A., and Gemski, P., K antigen and serum sensitivity of rough Escherichia coli. Infect Immun 37: 956–960 (1982).PubMedGoogle Scholar
  9. 9.
    Vermeulen, C., Cross, A., Byrne, W.R., and Zollinger, W., Quantitative relationship between capsular content and killing of K1-encapsulated E. coli. Abstr B247, American Society for Microbiology, National Meeting, Atlanta (1987).Google Scholar
  10. 10.
    Welch, W.D., Martin, W.J., Stevens, P., and Young, L.S., Relative opsonic and protective activities of antibodies against K1, 0 and lipid A antigens of Escherichia coli. Scand J Infect Dis 11: 291–301 (1979).Google Scholar
  11. 11.
    VanDijk, W.C., Verbrugh, H.A., van Erne-van der Tol, M.E., Peters, R., and Verhoef, J., Escherichia coli antibodies in opsonisation androtection against infection. J Med Microbiol 14: 381–389 (1981).CrossRefGoogle Scholar
  12. 12.
    Cross, A.S., Zollinger, W., Mandrell, R., Gemski, P., and Sadoff, J., Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli. J Infect Dis 147: 68–76 (1983).PubMedCrossRefGoogle Scholar
  13. 13.
    Kirkland, T.N. and Ziegler, E.J., An immunoprotective monoclonal antibody to lipopolysaccharide. J Immunol 132: 2590–2592 (1984).PubMedGoogle Scholar
  14. 14.
    Pluschke, G. and Achtman, M., Antibodies to 0 antigen of lipopoly saccharide are protective against neonatal infection with Escherichia coli K1. Infect Immun 49: 365–370 (1985).PubMedGoogle Scholar
  15. 15.
    Kaufman, B.M., Cross, A.S., Futrovsky, S.L., Sidberry, H.F., and Sadoff, J.C., Monoclonal antibodies reactive with K1-encapsulated E. coli lipopolysaccharide are opsonic and protect mice against lethal challenge. Infect Immun 52: 617–619 (1986).Google Scholar
  16. 16.
    Cross, A.S., Sadoff, J.C., Kaufman, B.M., and Zollinger, W., The use of monoclonal antibody combinations in the treatment of E. coli bacteremia. Abstr 124, 4th International Symposium on Infections in the Compromised Host, Ronneby Brunn, Sweden (1986).Google Scholar
  17. 17.
    Pluschke, G., Moll, A., Kusecek, B., Achtman, M., Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and monoclonal antibodies as tools for the subrouping of Escherichia coli lipopolysaccharide 018 and 023 antigens. Infect Immun 51: 286–293 (1986).PubMedGoogle Scholar
  18. 18.
    Cross, A.S., Gemski, P., Sadoff, J., Byrne, W., and Zollinger, W., Lipopolysaccharide as a virulence factor in LPS-hyporesponsive (C3B/BeJ) mice infected with K1-encapsulated E. coli. Abstr. 2151, FASEB National Meeting, Anaheim, California (1985).Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • A. Cross
    • 1
  • J. Sadoff
    • 1
  • P. Gemski
    • 2
  • Kwang Sik Kim
    • 3
  1. 1.Department of Bacterial DiseasesWalter Reed Army Institute of ResearchUSA
  2. 2.Department of Biological ChemistryWalter Reed Army Institute of ResearchUSA
  3. 3.Department of PediatricsChildrens Hospital of Los AngelesLos AngelesUSA

Personalised recommendations